Checkpoint Therapeutics Receives Approval for PD-L1 Therapy
December 16, 2024
The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
Recent Posts
May. 28, 2025
What’s New in Clinical Trials for Cutaneous Squamous Cell Carcinoma?
Apr. 23, 2025
Wide Local Excision vs. Mohs Surgery: A Dermatologist Explains
Mar. 31, 2025
Skin Cancer Risk Persists for 30 Years after Blood Cancer Diagnosis
Feb. 25, 2025
A Mohs Surgeon Explains the Procedure
Dec. 16, 2024